[Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma.
作者信息
Kratochwil Clemens, Giesel Frederik L, Rathke Hendrik, Fink Rebecca, Dendl Katharina, Debus Jürgen, Mier Walter, Jäger Dirk, Lindner Thomas, Haberkorn Uwe
机构信息
Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
出版信息
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):3011-3013. doi: 10.1007/s00259-021-05273-8. Epub 2021 Mar 17.
Abstract
摘要
相似文献
1
[Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma.钐标记的FAPI-46放射性配体疗法治疗一名患有肉瘤肺转移的患者。
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):3011-3013. doi: 10.1007/s00259-021-05273-8. Epub 2021 Mar 17.
2
High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.高活性钐-153-乙二胺四甲撑膦酸治疗不可切除骨肉瘤
Nuklearmedizin. 1999;38(8):337-40.
3
Elevated [Ga]Ga-DOTA-FAPI-04 activity in degenerative osteophyte in a patient with lung cancer.一名肺癌患者退变骨赘中[镓]镓-DOTA-FAPI-04活性升高。
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1671-1672. doi: 10.1007/s00259-020-05090-5. Epub 2020 Nov 12.
4
Elevated 68Ga-FAPI Accumulation in a Recurrent Angiomyolipoma.68Ga-FAPI 摄取增高的复发性血管平滑肌脂肪瘤。
Clin Nucl Med. 2020 Dec;45(12):1034-1035. doi: 10.1097/RLU.0000000000003345.
5
Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases.钐[153Sm]依替膦酸治疗骨转移患者的长期随访中的不良事件。
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):506-10. doi: 10.1016/j.ijrobp.2010.05.066. Epub 2010 Oct 1.
6
Comparison of Ga-FAPI and F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers.胃、十二指肠和结直肠癌症中 Ga-FAPI 与 F-FDG 摄取的比较。
Radiology. 2021 Feb;298(2):393-402. doi: 10.1148/radiol.2020203275. Epub 2020 Dec 1.
7
68Ga-FAPI PET/CT in Assessment of Leptomeningeal Metastases in a Patient With Lung Adenocarcinoma.68Ga-FAPI PET/CT 评估肺腺癌患者脑膜转移中的应用。
Clin Nucl Med. 2020 Oct;45(10):784-786. doi: 10.1097/RLU.0000000000003231.
8
Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.骨靶向放射性药物作为骨肉瘤的靶向制剂：钐-153-EDTMP 和镭-223。
Adv Exp Med Biol. 2014;804:291-304. doi: 10.1007/978-3-319-04843-7_16.
9
Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.钐-153 乙二胺四甲基膦酸（153Sm-EDTMP）：用于成骨性骨转移瘤和骨肉瘤的骨骼放疗
Expert Rev Anticancer Ther. 2007 Nov;7(11):1517-27. doi: 10.1586/14737140.7.11.1517.
10
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.高剂量钐-153 乙二胺四亚甲基膦酸盐：骨肉瘤和骨转移患者骨骼照射的低毒性
J Clin Oncol. 2002 Jan 1;20(1):189-96. doi: 10.1200/JCO.2002.20.1.189.
引用本文的文献
1
Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.癌症相关成纤维细胞：异质性、癌症发病机制及治疗靶点
MedComm (2020). 2025 Jul 11;6(7):e70292. doi: 10.1002/mco2.70292. eCollection 2025 Jul.
2
FAP-Directed Imaging and Therapy in Head and Neck Cancer of Unknown Primary.未知原发灶头颈部癌的FAP导向成像与治疗
Cancers (Basel). 2025 Jun 30;17(13):2205. doi: 10.3390/cancers17132205.
3
Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).成纤维细胞活化蛋白抑制剂正电子发射断层扫描（FAPI-PET）的临床应用
Npj Imaging. 2024 Nov 13;2(1):48. doi: 10.1038/s44303-024-00053-z.
4
Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.基于成纤维细胞活化蛋白抑制剂（FAPI）的诊疗一体化
Pharmaceuticals (Basel). 2025 Apr 3;18(4):522. doi: 10.3390/ph18040522.
5
Therapeutic potential of FAPI RLT in oncology: A systematic review.FAPI放射性配体疗法在肿瘤学中的治疗潜力：一项系统综述。
Theranostics. 2025 Mar 10;15(9):4084-4100. doi: 10.7150/thno.106108. eCollection 2025.
6
Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites.靶向具有白蛋白结合位点的成纤维细胞的放射性配体的开发与应用
Mol Cancer Ther. 2025 Aug 1;24(8):1186-1196. doi: 10.1158/1535-7163.MCT-24-1108.
7
Monovalent and Divalent Designs of Copper Radiotheranostics Targeting Fibroblast Activation Protein in Cancer.靶向癌症中成纤维细胞活化蛋白的铜放射性诊疗剂的单价和二价设计
Cancers (Basel). 2024 Dec 15;16(24):4180. doi: 10.3390/cancers16244180.
8
Radiosynthesis and identification of a molecular probe I-FAPI targeting cancer-associated fibroblasts.靶向癌症相关成纤维细胞的分子探针I-FAPI的放射性合成与鉴定
Front Oncol. 2024 Aug 30;14:1442601. doi: 10.3389/fonc.2024.1442601. eCollection 2024.
9
Diagnostic Performances of PET/CT Using Fibroblast Activation Protein Inhibitors in Patients with Primary and Metastatic Liver Tumors: A Comprehensive Literature Review.基于成纤维细胞激活蛋白抑制剂的 PET/CT 对原发性和转移性肝脏肿瘤患者的诊断性能：一项全面的文献综述。
Int J Mol Sci. 2024 Jun 29;25(13):7197. doi: 10.3390/ijms25137197.
10
Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects.成纤维细胞活化蛋白抑制剂-PET/CT的近期研究主题：临床与药理学方面
Ann Nucl Med. 2024 Jan;38(1):10-19. doi: 10.1007/s12149-023-01873-6. Epub 2023 Oct 20.
本文引用的文献
1
Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.镓-FAPI PET/CT：不同癌症患者中两种含 DOTA 的 FAP 靶向剂的生物分布和初步剂量估算。
J Nucl Med. 2019 Mar;60(3):386-392. doi: 10.2967/jnumed.118.215913. Epub 2018 Aug 2.
2
Virotherapy Research in Germany: From Engineering to Translation.德国病毒疗法研究：从工程到转化。
Hum Gene Ther. 2017 Oct;28(10):800-819. doi: 10.1089/hum.2017.138.
3
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.针对癌症异质性的个体化新抗原疫苗。
Clin Cancer Res. 2016 Apr 15;22(8):1885-96. doi: 10.1158/1078-0432.CCR-15-1509.
4
Fibroblast activation protein: A potential therapeutic target in cancer.成纤维细胞激活蛋白：癌症治疗的潜在靶点。
Cancer Biol Ther. 2012 Feb 1;13(3):123-9. doi: 10.4161/cbt.13.3.18696.
5
Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.成纤维细胞激活蛋白和二肽基肽酶-IV 在人类骨和软组织肿瘤中的组织发生特异性表达。
Histopathology. 2009 Oct;55(4):432-40. doi: 10.1111/j.1365-2559.2009.03399.x.
Zotero 插件